Dynavax Technologies (NASDAQ:DVAX) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday, January 25th.
Several other brokerages have also weighed in on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Monday, November 19th. Royal Bank of Canada increased their price objective on shares of Dynavax Technologies to $26.00 and gave the company an “outperform” rating in a report on Monday, October 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Monday, October 1st. Finally, ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, November 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Dynavax Technologies currently has an average rating of “Hold” and an average price target of $28.00.
NASDAQ DVAX traded up $0.02 during trading hours on Friday, hitting $10.99. The company’s stock had a trading volume of 331,164 shares, compared to its average volume of 828,225. Dynavax Technologies has a twelve month low of $7.85 and a twelve month high of $22.80. The firm has a market capitalization of $686.46 million, a P/E ratio of -6.35 and a beta of 0.79. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.29 and a quick ratio of 5.90.
Institutional investors and hedge funds have recently bought and sold shares of the business. Advisor Group Inc. raised its holdings in Dynavax Technologies by 515.3% in the fourth quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 3,746 shares during the period. Legal & General Group Plc increased its position in shares of Dynavax Technologies by 18.7% during the fourth quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 1,860 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Dynavax Technologies during the fourth quarter worth $117,000. Quantbot Technologies LP bought a new stake in shares of Dynavax Technologies during the third quarter worth $131,000. Finally, Pacer Advisors Inc. bought a new stake in shares of Dynavax Technologies during the third quarter worth $132,000. Institutional investors own 75.53% of the company’s stock.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Further Reading: Cost of Goods Sold (COGS)
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.